Bibliography
- YOUNKIN SG: Amyloid β vaccination: reduced plaques and improved cognition. Nat. Med. (2001) 7:18-19.
- HAASS C: New hope for Alzheimer’s disease vaccine. Nat. Med. (2002) 8:1195-1196.
- PFEIFER M, BONCRISTIANO S, BONDOLFI L et al.: Cerebral hemorrhage after passive anti-Aβ immunotherapy. Science (2002) 298:1379.
- NICOLL JA, WILKINSON D, HOLMES C et al.: Neuropathology of human Alzheimer’s disease after immunization with amyloid-β peptide: a case report. Nat. Med. (2003) 9:448-452.
- IWATSUBO T, ODAKA A, SUZUKI N, MIZUSAWA H, NUKINA N, IHARA Y: Visualization of Aβ42(43) and Aβ40 in senile plaques with end specific Aβ monoclonals: evidence that an initially deposited species is Aβ42 (43). Neuron (1994) 13:45-53.
- GRAVINA SA, HO L, ECKMAN CB et al.: Amyloid β protein (Aβ) in Alzheimer’s disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at Aβ40 or Aβ42 (43). J. Biol. Chem. (1995) 270:7013-7016.
- GOLDE TE, ECKMAN CB, YOUNKIN SG: Biochemical detection of Aβ isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer’s disease. Biochim. Biophys. Acta. (2000) 1502:172-187.
- KLEIN WL, STINE WB Jr, TEPLOW DB: Small assemblies of unmodified amyloid β-protein are the proximate neurotoxin in Alzheimer’s disease. Neurobiol. Aging (2004) 25:569-580.
- WALSH DM, SELKOE DJ: Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept. Lett. (2004) 11:213-228.
- YOUNKIN SG: The role of Aβ42 in Alzheimer’s disease. J. Physiol. Paris (1998) 92:289-292.
- LEVITES Y, DAS P, PRICE RW et al.: Anti-Aβ42- and anti-Aβ40-specific mAbs attenuate amyloid deposition in an Alzheimer’s disease mouse model. J. Clin. Invest. (2006) 116(1):193-201.
- GLENNER GG, WONG CW: Alzheimer’s disease and Down’s syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. (1984) 122(3):1131-1135.
- WILCOCK DM, ROJIANI A, ROSENTHAL A et al.: Passive immunotherapy against Aβ in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J. Neuroinflammation (2004) 1:24.
- HOCK C, KONIETZKO U, STREFFER JR et al.: Antibodies against β-amyloid slow cognitive decline in Alzheimer’s disease. Neuron (2003) 38:547-554.
- BUSSIERE T, BARD F, BARBOUR R et al.: Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Aβ immunotherapy on their clearance. Am. J. Pathol. (2004). 165:987-995.
- ASAMI-ODAKA A, OBAYASHI-ADACHI Y, MATSUMOTO Y et al.: Passive immunization of the Aβ42(43) C-terminal-specific antibody BC05 in a mouse model of Alzheimer’s disease. Neurodegen. Dis. (2005) 2:36-43.
- BARD F, BARBOUR R, CANNON C et al.: Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer’s disease-like neuropathology. Proc. Natl. Acad. Sci. USA (2003) 100:2023-2028.
- DAS P, MURPHY MP, YOUNKIN LH et al.: Reduced effectiveness of Aβ1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol. Aging (2001) 22:721-727.
- GILMAN S, KOLLER M, BLACK RS et al.: Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology (2005) 64:1553-1562.
- TYCKO R, ISHII Y: Constraints on supramolecular structure in amyloid fibrils from two-dimensional solid-state NMR spectroscopy with uniform isotopic labeling. J. Am. Chem. Soc. (2003) 125:6606-6607.